MELBOURNE, Australia and INDIANAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that it will release its full year results for the period ended 31 December 2025 on Friday, 20 February 2026 AEDT (Thursday, 19 February 2026 EST). An investor webcast and conference call will be held at 9:30 a.m. AEDT, Friday, 20 February 2026 (5:30 p.m. EST, Thursday, 19 February 2026). Participants can register at the following link: https://edge.media-server.com ...

Telix Pharmaceuticals Limited (NASDAQ:TLX) , a therapeutic and diagnostic radiopharmaceuticals company, on Tuesday reported its full-year revenue. • Telix Pharmaceuticals stock is testing lower boundaries. Why is TLX stock at lows?Telix Hits FY 2025 Revenue TargetAustralia-based Telix Pharmaceuticals reported fiscal 2025 revenue of approximately $804 million, aligning with its upgraded guidance of $800-$820 million.The company also noted a significant 46% year-over-year increase in the fourth quarter revenu ...

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday.Shares of Netflix Inc (NASDAQ:NFLX) fell sharply in pre-market trading after the company reported fourth-quarter financial results and issued first-quarter guidance below estimates.Netflix reported better-than-expected fourth-quarter financial results Tuesday after market close. Netflix said it sees first-quarter revenue of $12.16 billion versus a Street consensus estimate of $12.19 billion, according to data f ...

MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides an update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4 2025). Q4 2025 Highlights Full-year (FY) 2025 unaudited Group revenue of approximately US$804 million (A$1.2 billion1), in line with upgraded guidance of US$800-$820 million2 (previously US$770-800 million).Q4 2025 unaudited Group revenue of approximately US$208 mill ...

MELBOURNE, Australia, Jan. 17, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study), a Phase 3 trial to evaluate the use of Telix’s commercial PSMA-PET1 imaging agents, Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) and Gozellix® (kit for the preparation of gallium Ga 68 gozetotide injection) in the ...

Company Overview - Telix is an increasingly recognized company in the radiopharmaceutical space, focusing solely on oncology and radiopharmaceuticals with a precision medicine-oriented approach [2][3] - The company is vertically integrated, which allows it to control various aspects of its operations in the radiopharma sector [2] Product Development Strategy - Telix develops both imaging agents and therapeutic agents for each target, leveraging the valuable signals obtained from radiopharmaceuticals to understand efficacy and improve delivery [3][4] - This dual approach of combining imaging and therapeutic capabilities has proven beneficial for the company's commercial trajectory [4]

Telix Pharmaceuticals (NasdaqGS:TLX) FY Conference January 12, 2026 12:00 PM ET Company ParticipantsChristian Behrenbruch - CEOConference Call ParticipantsChris Cooper - AnalystNone - AnalystChris CooperWe'll have some important FDA meetings.Christian BehrenbruchOkay.Chris CooperOkay, good morning. Thanks for joining us here at the J.P. Morgan Healthcare Conference. My name is Chris Cooper. I cover Australian healthcare here at J.P. Morgan. For this session, we're very fortunate to be joined by Christian Be ...

This presentation should be read together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the U ...

Core Viewpoint - A class action securities lawsuit has been filed against Telix Pharmaceuticals Ltd. alleging securities fraud that affected investors between February 21, 2025, and August 28, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that defendants made false statements regarding Telix's progress with prostate cancer therapeutic candidates, overstated the quality of its supply chain and partners, and that these statements were materially false and misleading [2]. - Investors who suffered losses during the specified timeframe have until January 9, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. Group 2: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Limited for allegedly making false and misleading statements regarding its business operations and prospects during the Class Period from February 21, 2025, to August 28, 2025 [3][7]. Allegation Details - The lawsuit claims that defendants materially overstated the progress of Telix's prostate cancer therapeutic candidates [3]. - It is alleged that the quality of Telix's supply chain and partners was also overstated [3]. - As a result of these misrepresentations, statements about Telix's business and operations were materially false and misleading, leading to investor damages when the true details emerged [3]. Next Steps - Investors who purchased Telix shares and suffered losses are encouraged to contact the law firm for more information or to discuss their rights [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is January 9, 2026 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5]. - The firm has offices in New York, California, and South Carolina, and specializes in commercial and securities litigation [5].